Pregnancy is associated with a long-term reduction in breast cancer risk ([@bib13]). The underlying mechanisms are not fully understood, but the reduced risk has been attributed to the differentiation of breast tissue cells induced by pregnancy hormones ([@bib4]). To improve our understanding of the role of pregnancy in breast cancer development, some investigators have studied long-term effects of certain pregnancy characteristics or complications ([@bib18]), including hypertensive disorders in pregnancy such as preeclampsia and gestational hypertension.

Preeclampsia is clinically characterised by hypertension and proteinuria in the second half of pregnancy, and occurs in about 5% of primiparous women ([@bib26]). Gestational hypertension and preeclampsia appear to be closely related conditions that may originate from the same underlying disorder ([@bib34]). Studies that have examined the association of preeclampsia and/or hypertension in pregnancy with later breast cancer risk have shown conflicting results and variously reported reduced risk ([@bib20]; [@bib25]; [@bib28]; [@bib7]; [@bib31], [@bib30]; [@bib12]; [@bib24]), no association ([@bib17]; [@bib6]; [@bib15]), or an increased risk ([@bib22]; [@bib5]). Limitations of most previous studies include a relatively young age of the participants and a small number of exposed women who have later developed breast cancer.

It is not known whether an association of hypertensive diseases in pregnancy with later breast cancer risk may be attributed to events during that particular pregnancy, or to underlying traits that are both associated with susceptibility to pregnancy hypertension and with breast cancer risk ([@bib11]; [@bib18]). If the association of pregnancy hypertensive diseases with breast cancer risk differs depending on offspring sex ([@bib24]; [@bib27]; [@bib30]), on the number of hypertensive pregnancies ([@bib24]), or on the severity of the hypertensive condition ([@bib31]; [@bib24]), this may support a pregnancy-specific effect.

We have updated and extended the Norwegian data ([@bib31]; [@bib30]) with an addition of 218 706 participants and 6696 breast cancer cases, based on a linkage between the Medical Birth Registry of Norway and the Cancer Registry of Norway, and investigated the association of hypertensive diseases in pregnancy with later breast cancer risk. The increased statistical power enabled us to obtain more precise estimates for the previously reported associations. In addition, we have investigated whether the association is similar for hypertensive diseases in the first and in any pregnancy, whether the association could be modified by subgroup or severity of hypertensive disease, and whether a dose-risk association could be present, as indicated by the recurrence of hypertensive disease in pregnancy.

Methods
=======

Study population
----------------

Data were obtained from the Medical Birth Registry of Norway and the Cancer Registry of Norway. In the Medical Birth Registry, information on all births has been collected since 1967, and recorded in a standardised notification form completed by midwives and doctors. A total of 972 331 women who gave their first birth between 1 January 1967 and 31 December 2008, and had singleton births only, were eligible for follow-up. We excluded 96 women who were diagnosed with breast cancer before their first birth and 2481 women who had a period of emigration before their first birth, and thus could not be followed for breast cancer occurrence before their first birth. We also excluded 50 042 women (5%) with missing information on the following factors related to their first pregnancy: duration of pregnancy, offspring sex, and offspring birth weight. The remaining 919 712 women were followed for breast cancer occurrence.

Study factors
-------------

During the study period (1967--2008), nearly 100% of pregnant women in Norway have attended the publicly financed routine antenatal care ([@bib1]). At each visit, blood pressure is measured and urine is examined for protein. Information from these visits and from medical examinations at the delivery unit is included in the notification form that is sent to the Medical Birth Registry. Hypertensive diseases in pregnancy are classified according to the International Classification of Diseases (ICD): ICD-8 was used throughout 1998, and ICD-10 from 1999. Hypertensive diseases in pregnancy were defined as hypertension in pregnancy (ICD-8: 637.0 and 637.2, ICD-10: O16) and as preeclampsia/eclampsia (ICD-8: 637.4--9, ICD-10: O13, O14 and O15; [@bib19]).

From the Medical Birth Registry, we also obtained information on the following factors: date of delivery, age at first birth, total number of pregnancies, offspring\'s birth weight in grams, offspring sex, and duration of pregnancy in completed weeks (based on ultrasound examination in 24% of the pregnancies and on the first day of the last menstrual period in 76%).

Follow-up
---------

The unique identification number of Norwegian citizens was used to link information from the Medical Birth Registry to information on cancer occurrence from the Cancer Registry of Norway, which also includes information on vital status and emigration, as recorded by the Population Registry at Statistics Norway. Invasive breast cancer was registered according to the ICD, 7th edition (ICD-7, code 170). Breast cancer diagnoses were based on histological (99.4%), cytological (0.5%), or clinical (0.1%) examination. Reporting of new diagnoses of cancer to the Cancer Registry is mandatory by law, and follow-up for breast cancer is considered practically complete ([@bib14]). Women were followed from their first birth until the date of breast cancer diagnosis, death, emigration, or until 31 December 2008, whichever came first.

The study was approved by the regional committee for medical research ethics.

Statistical analyses
--------------------

The association of hypertensive diseases in pregnancy with breast cancer incidence was assessed using the Cox proportional hazards models to estimate hazard ratios (HRs) with 95% confidence intervals (CI). We studied the association of preeclampsia/eclampsia (PE) and hypertension (HIP) in a woman\'s first pregnancy with breast cancer risk, both using PE and HIP combined, and as separate entities. We also investigated whether PE/HIP in any pregnancy was associated with the risk of breast cancer, where women contributed person-time to the exposed category from their first registered PE/HIP pregnancy. Among women with two or more births, we also investigated the association of PE/HIP in the first or second pregnancy, and in both pregnancies.

To investigate whether the association could vary by menopausal status at diagnosis, we conducted separate analyses with follow-up until 50 years of age (\<50 years) and beyond 50 years (⩾50 years), using 50 years as a crude indicator for menopausal status. We also conducted a sensitivity analysis for women followed from 60 years of age. Also, we studied whether the association of PE/HIP in the first pregnancy could be modified by duration of pregnancy (\<37 or ⩾37 weeks), offspring birth weight (\<3000, 3000--3999 or ⩾4000 g), and by offspring sex.

In a separate analysis, we studied whether the duration of a woman\'s first pregnancy was associated with breast cancer risk, stratified by whether PE/HIP occurred or not in the first pregnancy. The aim of this analysis was to clarify the role of preterm birth for the association of PE/HIP with breast cancer risk. Analyses of trend were performed by scoring each category of duration of pregnancy with the median value within that category. In the analysis, the categories were treated as a continuous variable, and we estimated HRs with 95% CI per week of longer duration of pregnancy.

For all analyses, attained age was used as the time scale. We adjusted for maternal birth year (in 5-year categories), age at first birth (\<20, 20--24, 25--29, 30--34, or ⩾35 years), parity (1, 2, 3, 4, or ⩾5), and marital status at first birth (married/cohabiting or single). Parity was treated as a time-dependent variable; thus, a woman entered a category of higher parity whenever a new birth occurred. We assessed heterogeneity of the HRs across strata of the different pregnancy characteristics by likelihood ratio tests, and compared models with and without product terms.

Proportionality between hazards was checked by comparing log minus log plots of survival and by performing tests based on Schoenfeld residuals. Assumptions were met for all the previously described models. In a sensitivity analysis, we investigated whether inclusion of women with missing information on offspring birth weight and sex, and duration of pregnancy, could alter the main results.

All analyses were conducted using Stata version 11.1 MP for Windows (Stata Corp., College Station, TX, USA).

Results
=======

A total of 919 712 women without breast cancer at baseline were followed for approximately 19 million person years. Median time of follow-up was 20.4 years (interquartile range (IQR) 10.0--31.8 years) for women with a normotensive first pregnancy, and 17.8 (IQR 7.7--28.7 years) for women with PE/HIP in the first pregnancy. The difference in follow-up time was largely explained by an increase in the frequency of PE/HIP during the observation period. During follow-up, 15 856 women were diagnosed with invasive breast cancer. Mean age at diagnosis was similar in the two groups (49.0 years, s.d. 8.4 years). Women with PE/HIP in their first pregnancy were older at first birth, had pregnancies of shorter duration, their children were smaller, and there was a higher proportion of male offspring after PE/HIP compared with normotensive first pregnancies. Characteristics of the study participants are shown in [Table 1](#tbl1){ref-type="table"}.

Women who had a hypertensive disease in their first pregnancy were at 17% lower risk of breast cancer than women with a normotensive first pregnancy (HR 0.83, 95% CI 0.77, 0.90; [Table 2](#tbl2){ref-type="table"}). The lower risk was present both for isolated hypertension (HR 0.78, 95% CI 0.68, 0.89) and for PE (HR 0.86, 95% CI 0.79, 0.94). Estimates were similar for women who had PE/HIP in the first and second pregnancy (HR 0.84, 95% CI 0.70, 1.01) and for women with PE/HIP in any pregnancy (HR 0.84, 95% CI 0.79, 0.89). The associations were similar for breast cancer diagnosed before and after 50 years of age ([Table 3](#tbl3){ref-type="table"}), and for women 60 years and older (results not shown).

[Tables 4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"} show associations of PE/HIP in first pregnancy according to pregnancy characteristics and offspring sex. There was no evidence for a stronger association related to the severity of hypertension, as indicated by preterm birth or low offspring birth weight. In fact, the association was more pronounced among women with average offspring birth weight (HR 0.77, 95% CI 0.69, 0.85), and the negative association was restricted to women who gave birth after 37 completed weeks of pregnancy (HR 0.81, 95% CI 0.75, 0.88). Overall, women with PE/HIP in their first pregnancy were at reduced risk of breast cancer, regardless of whether their offspring was a male (HR 0.80, 95% CI 0.72, 0.88) or a female (HR 0.88, 95% CI 0.79, 0.97), and there was no clear risk difference by offspring sex among women who gave birth after 37 weeks. However, among women with a preterm first birth, the reduced breast cancer risk associated with PE/HIP was restricted to women with a male offspring.

[Table 6](#tbl6){ref-type="table"} shows duration of first pregnancy in relation to breast cancer risk, stratified by PE/HIP status. There was a reduction in risk with increasing duration of first pregnancy, and the inverse association was more pronounced among women with PE/HIP than among normotensive women (HR per week longer duration 0.95, 95% CI 0.93, 0.98 and 0.99, and 95% CI 0.98, 1.00, respectively). Crude absolute incidence rates among women whose first pregnancy was shorter than 32 weeks were similar, regardless of the PE/HIP status.

In all analyses, adjustment for potentially confounding factors marginally strengthened the associations, compared with models with adjustment for age alone. There was no change in the main results when women with missing information on offspring birth weight and sex, and duration of pregnancy were included in the analyses.

Discussion
==========

In this prospective study of 919 712 women, hypertensive diseases in pregnancy was associated with a reduced risk of breast cancer, of a similar magnitude as previously reported ([@bib31], [@bib30]). The reduced risk was similar for PE/HIP in the first pregnancy, in any pregnancy, and for recurrent PE/HIP, and for breast cancer diagnosed both before and after 50 years of age. The lowest risk was observed for women who developed PE/HIP and had a term or post-term birth, or a child of average birth weight.

Our results correspond to those of most previous studies in reporting a moderately reduced risk ([@bib20]; [@bib25]; [@bib28]; [@bib7]; [@bib12]; [@bib24]), regardless of whether preeclampsia ([@bib20]; [@bib28]; [@bib7]; [@bib12]; [@bib24]) or hypertension in pregnancy ([@bib25]; [@bib28]; [@bib7]; [@bib24]) was studied. All but one ([@bib7]) of those studies had a retrospective design, and the assessment of hypertensive disease in pregnancy was based on patients\' recall in some studies ([@bib25]; [@bib28]; [@bib24]) and on hospital records in others ([@bib20]; [@bib7]; [@bib12]). However, in a Swedish registry-based study using prospective data, the investigators found no association for hypertensive diseases combined, but estimates were not adjusted for other potentially confounding factors ([@bib6]). In two other prospective studies, there was no association of self-reported ([@bib15]) or registry-based ([@bib17]) preeclampsia with breast cancer risk. In a hospital-based prospective study from Israel ([@bib5]) and in a retrospective study from Italy, based on self-reported data ([@bib22]), the researchers reported an increased risk of breast cancer associated with preeclampsia and hypertensive disease in pregnancy, respectively. The reasons for the divergence in results between studies are unclear, but may be related to study size, exposure definition, lack of adjustment for potential confounding, genetic factors, or to modification by unmeasured or unknown factors. For simplicity, characteristics and main results of the referred previous studies are summarised in [Table 7](#tbl7){ref-type="table"}.

Our study encompassed all women who gave their first birth in Norway during the study period, and information on incident breast cancer was collected prospectively. Therefore, bias in selection or information recall is unlikely. Misclassification of breast cancer diagnoses is most likely negligible, as reporting of cancer to the Cancer Registry of Norway is mandatory by law, and the breast cancer diagnoses were based on pathology reports for 99.9% of the women for whom a breast cancer diagnosis was reported.

We did not have information on body mass index, which could have confounded the association of hypertensive conditions in pregnancy with breast cancer risk ([@bib18]). Overweight and obesity are associated with an increased risk of developing hypertensive diseases during pregnancy ([@bib34]), and a high body mass index during the reproductive years is associated with reduced risk of premenopausal breast cancer ([@bib9]). For postmenopausal women, overweight is generally associated with an increased risk ([@bib9]), although there are indications that overweight at a young age may be associated with a modestly reduced risk, of postmenopausal breast cancer ([@bib2]). We found a similar reduction in risk both before and after 50 years of age, which may suggest that the association cannot be fully attributed to confounding by overweight. The results of one study indicated that adjustment for body mass index may attenuate the association of hypertensive diseases in pregnancy with breast cancer risk among premenopausal, but not in postmenopausal women ([@bib24]). However, in most studies that have been able to evaluate the possible confounding by body mass index, estimates have remained unchanged after adjustment ([@bib25]; [@bib22]; [@bib28]; [@bib15]). Other potentially confounding factors include insulin resistance and diabetes mellitus, which are strongly related to the risk of preeclampsia ([@bib21]) and may also be related to breast cancer risk ([@bib3]).

The accuracy of the exposure in our study has not been validated. The diagnostic criteria for preeclampsia have changed over time and are still debated ([@bib26]). Although some misclassification may have occurred, it is likely to be non-differential with respect to future breast cancer diagnosis, and its effect would lead to conservative estimates. We had no direct information on menopausal status, but used 50 years of age as a crude indicator. In addition, the cohort is still relatively young. This could have obscured potential differences in association by menopausal status, but the similarly reduced risks for women 60 years or older suggest that the association was not likely to be modified by menopausal status. We used duration of pregnancy as an indicator for the severity of hypertensive disease in pregnancy. Because of the induction of labour in women with a severe hypertensive disease, duration of pregnancy may be regarded as an intermediate variable, and we cannot exclude the possibility that this may introduce a bias ([@bib8]). However, duration of pregnancy is not strongly related to breast cancer risk, and therefore, the potential bias would be negligible. Finally, our results should be interpreted considering that multiple tests were carried out, and although these were related, chance findings cannot be ruled out.

There is an inverse association of parity with breast cancer risk, where each additional pregnancy confers additional protection. This effect has been attributed to the repeated exposure to pregnancy hormones ([@bib13]). If pregnancy hypertensive diseases influence breast cancer risk through pregnancy-specific events, such as altering the hormonal milieu compared with that of normotensive pregnancies ([@bib11]; [@bib23]), one might expect that women who experience more than one hypertensive pregnancy would be at particularly low risk. However, the risk reduction among women with recurrent hypertensive disease in pregnancy was not particularly strong, in contrast to reports by others ([@bib24]).

Possible differences in the association by offspring sex were weaker in this analysis than previously reported ([@bib30]). In preeclampsia, the duration of pregnancy tends to be longer if the fetus is a male ([@bib33]), but it is unclear whether this puzzling phenomenon could disturb the sex-specific analyses of hypertensive diseases and breast cancer risk.

The inverse association of duration of first pregnancy with breast cancer risk was slightly attenuated compared with what has previously been reported ([@bib32]). A possible impact of duration of pregnancy on breast cancer risk has been attributed to increased differentiation of breast tissue in women with longer exposure to pregnancy hormones ([@bib18]). In our study, the association was particularly strong among women who had a hypertensive disease in their first pregnancy. Preeclampsia is thought to originate from an abnormal placentation and/or an abnormal maternal response to the pregnancy ([@bib26]). There are indications that early preeclampsia may be more closely associated with placental dysfunction than preeclampsia detected at term, and that term preeclampsia may be more strongly related to maternal metabolic factors ([@bib10]; [@bib29]), such as overweight and obesity ([@bib21]). Furthermore, risk factors for preeclampsia are associated with patterns of blood pressure change in normotensive pregnancies similar to those seen in preeclampsia ([@bib16]), and gestational hypertension and preeclampsia may be closely related conditions ([@bib34]). The lower breast cancer risk observed for women who experienced hypertension or preeclampsia in their first pregnancy and had a term or post-term birth may indicate that maternal metabolic factors may have an important role.

In conclusion, women who experience hypertensive diseases in pregnancy are at reduced risk of breast cancer. Further research is needed to clarify whether this association can be attributed to pregnancy-specific events or to underlying biological traits. A better understanding of how hypertensive diseases in pregnancy influence breast cancer risk may be useful for our understanding of breast cancer development.
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###### Characteristics of the study participants, according to presence or absence of hypertensive disease in first pregnancy

                                                                       **Normotensive**    **PE/HIP**
  -------------------------------------------------------------------- ------------------- -------------------
  Median time in study (IQR)                                           20.4 (10.0--31.8)   17.8 (7.7--28.7)
                                                                                            
  Mean age at breast cancer diagnosis (s.d.)                           49.0 (8.4)          48.9 (8.8)
                                                                                            
  Median birth year (IQR)                                              1962 (1953--1971)   1964 (1955--1973)
                                                                                            
  *Age at first birth, years*                                                              
   \<20                                                                107 734 (12.5)      5595 (9.9)
   20--24                                                              341 394 (39.5)      20 329 (36.0)
   25--29                                                              274 815 (31.8)      18 853 (33.4)
   30--34                                                              107 038 (12.4)      8352 (14.8)
   ⩾35                                                                 32 341 (3.7)        3277 (5.8)
                                                                                            
  *Parity*                                                                                 
   1                                                                   202 401 (23.4)      15 890 (28.2)
   2                                                                   401 324 (46.5)      25 673 (45.5)
   3                                                                   200 802 (23.3)      11 612 (20.6)
   4                                                                   46 271 (5.4)        2576 (4.6)
   ⩾5                                                                  12 509 (1.4)        654 (1.2)
                                                                                            
  *Offspring sex in first pregnancy*                                                       
   Male                                                                443 529 (51.4)      29 901 (53.0)
   Female                                                              419 778 (48.6)      26 504 (47.0)
                                                                                            
  *Birth weight in first pregnancy (g)*                                                    
   \<3000                                                              143 408 (16.6)      18 417 (32.7)
   3000--4000                                                          597 668 (69.2)      30 399 (53.9)
   ⩾4000                                                               122 246 (14.2)      7590 (13.5)
                                                                                            
  *Duration of first pregnancy*[a](#t1-fn3){ref-type="fn"} *(weeks)*                       
   \<37                                                                50 005 (5.8)        8704 (15.4)
   ⩾37                                                                 813 17 (94.2)       47 702 (84.6)
                                                                                            
  *Marital status at first birth*                                                          
   Married/cohabiting                                                  719 525 (83.3)      48 266 (85.6)
   Single                                                              143 782 (16.7)      8139 (14.4)

Abbreviations: HIP=hypertension in pregnancy; IQR=interquartile range; PE=preeclampsia/eclampsia.

Number of women (%).

Based on ultrasound examination in 24% of the pregnancies and on the first day of the last menstrual period in 76%.

###### Hypertensive diseases in pregnancy (PE/HIP) and breast cancer risk in 919 712 Norwegian women

                                                                         **Person-years**   **Cases**   **Rate[a](#t2-fn2){ref-type="fn"}**   **HR[b](#t2-fn3){ref-type="fn"}** **(95% CI)**   **HR[c](#t2-fn4){ref-type="fn"} (95% CI)**
  ---------------------------------------------------------------------- ------------------ ----------- ------------------------------------- ------------------------------------------------ --------------------------------------------
  *PE/HIP in first pregnancy*                                                                                                                                                                  
   No                                                                    17 919 955         15 113      84                                    1 (ref)                                          1 (ref)
   Yes                                                                   1 047 052          743         71                                    0.86 (0.80, 0.92)                                0.83 (0.77, 0.90)
    HIP                                                                  331 494            237         71                                    0.81 (0.71, 0.92)                                0.78 (0.68, 0.89)
    PE                                                                   715 559            506         71                                    0.88 (0.81, 0.97)                                0.86 (0.79, 0.94)
                                                                                                                                                                                                
  *PE/HIP in first and/or second pregnancy*[d](#t2-fn5){ref-type="fn"}                                                                                                                         
   No                                                                    12 458 204         11 758      94                                    1 (ref)                                          1 (ref)
   PE/HIP in first, but not second pregnancy                             558 440            435         78                                    0.86 (0.78, 0.95)                                0.85 (0.77, 0.93)
   PE/HIP in second, but not first pregnancy                             259 294            241         93                                    0.93 (0.82, 1.06)                                0.91 (0.80, 1.03)
   PE/HIP in first and second pregnancy                                  140 131            117         83                                    0.89 (0.74, 1.07)                                0.84 (0.70, 1.01)
                                                                                                                                                                                                
  *PE/hypertension in any pregnancy*                                                                                                                                                           
   Never                                                                 17 533 025         14 773      84                                    1 (ref)                                          1 (ref)
   Ever                                                                  1 433 982          1083        76                                    0.84 (0.79, 0.89)                                0.84 (0.79, 0.89)

Abbreviations: CI=confidence intervals; HIP=hypertension in pregnancy; HR=hazard ratio; PE=preeclampsia/eclampsia.

Cases/100 000 person-years, unadjusted.

Adjusted for age.

Adjusted for age, birth cohort, parity, age at first birth, and marital status at first birth.

Women with two or more pregnancies, followed from the date of their second birth.

###### Hypertensive diseases in pregnancy (PE/HIP) and breast cancer risk in 919 712 Norwegian women, stratified by age

                                                                                  **Premenopausal (\<50 years)**   **Postmenopausal (⩾50 years)**                                    
  ------------------------------------------------------------------------------- -------------------------------- -------------------------------- ------------------- ------ ----- -------------------
  *PE/HIP in first pregnancy*                                                                                                                                                        
   No                                                                             8013                             53                               1 (ref)             7038   264   1 (ref)
   Yes                                                                            405                              45                               0.84 (0.76, 0.93)   337    228   0.83 (0.75, 0.93)
    HIP                                                                           130                              46                               0.81 (0.68, 0.96)   106    206   0.75 (0.62, 0.91)
    PE                                                                            275                              44                               0.86 (0.76, 0.97)   231    240   0.88 (0.77, 1.00)
                                                                                                                                                                                      
  *PE/hypertension in first and/or second pregnancy*[c](#t3-fn4){ref-type="fn"}                                                                                                      
   No                                                                             6281                             61                               1 (ref)             5427   255   1 (ref)
   PE/HIP in first, but not second pregnancy                                      237                              50                               0.83 (0.73, 0.94)   197    227   0.88 (0.76, 1.01)
   PE/HIP in second, but not first pregnancy                                      126                              60                               0.91 (0.76, 1.08)   114    239   0.91 (0.75, 1.07)
   PE/HIP in first and second pregnancy                                           69                               59                               0.89 (0.70, 1.13)   48     213   0.79 (0.59, 1.08)
                                                                                                                                                                                      
  *PE/HIP in any pregnancy*                                                                                                                                                          
   Never                                                                          7841                             52                               1 (ref)             6871   266   1 (ref)
   Ever                                                                           577                              48                               0.84 (0.77, 0.91)   504    224   0.85 (0.77, 0.93)

Abbreviations: CI=confidence intervals; HIP=hypertension in pregnancy; HR=hazard ratio; PE=preeclampsia/eclampsia.

Cases/100 000 person-years, unadjusted.

Adjusted for age, birth cohort, parity, age at first birth, and marital status at first birth.

Women with two or more pregnancies, followed from the date of their second birth in analyses of women \<50 years, and from age 50 years in analyses of women ⩾50 years.

###### PE/HIP in first pregnancy and breast cancer risk in 919 712 Norwegian women, stratified by offspring birth weight and duration of pregnancy

  **Pregnancy characteristic**                                      **PE/HIP in first pregnancy**   **Cases**   **Rate**[a](#t4-fn2){ref-type="fn"}   **HR**[b](#t4-fn3){ref-type="fn"} **(95% CI)**
  ----------------------------------------------------------------- ------------------------------- ----------- ------------------------------------- ------------------------------------------------
  *Offspring birth weight*[c](#t4-fn4){ref-type="fn"} *(in g)*                                                                                        
   \<3000                                                           Normotensive                    2695        88                                    1 (ref)
                                                                    PE/HIP                          273         82                                    0.92 (0.81, 1.05)
                                                                                                                                                       
   3000--3999                                                       Normotensive                    10 405      84                                    1 (ref)
                                                                    PE/HIP                          369         64                                    0.77 (0.69, 0.85)
                                                                                                                                                       
   ⩾4000                                                            Normotensive                    2013        84                                    1 (ref)
                                                                    PE/HIP                          101         73                                    0.86 (0.71, 1.05)
                                                                                                                                                       
  *Duration of pregnancy*[d](#t4-fn5){ref-type="fn"} *(in weeks)*                                                                                     
   ⩾37                                                              Normotensive                    14 189      84                                    1 (ref)
                                                                    PE/HIP                          629         69                                    0.81 (0.75, 0.88)
                                                                                                                                                       
   \<37                                                             Normotensive                    924         89                                    1 (ref)
                                                                    PE/HIP                          114         85                                    0.96 (0.79, 1.17)

Abbreviations: CI=confidence intervals; HIP=hypertension in pregnancy; HR=hazard ratio; PE=preeclampsia/eclampsia.

Cases/100 000 person-years, unadjusted.

Adjusted for age, birth cohort, parity, age at first birth and marital status at first birth.

*P*-value from LR-test of interaction term 0.16.

*P*-value from LR-test of interaction term 0.09.

###### PE/HIP in first pregnancy and breast cancer risk in 919 712 Norwegian women, stratified by offspring sex

                                                               **Male offspring**   **Female offspring**                                  
  ----------------------------------------------------------- -------------------- ---------------------- ------------------- ------ ---- -------------------
  *PE/HIP in first pregnancy*[c](#t5-fn4){ref-type="fn"}                                                                                  
  * *No                                                               7794                   85                 1 (ref)        7319   84        1 (ref)
  * *Yes                                                              379                    68            0.80 (0.72, 0.88)   364    74   0.88 (0.79, 0.97)
                                                                                                                                                    
  *PE/HIP in first pregnancy*                                                                                                             
  * *⩾37 weeks and normotensive[d](#t5-fn5){ref-type="fn"}            7283                   84                 1 (ref)        6906   84        1 (ref)
  * *⩾37 weeks and PE/HIP                                             326                    67            0.79 (0.70, 0.88)   303    71   0.83 (0.74, 0.94)
                                                                                                                                                    
  * *\<37 weeks and normotensive[e](#t5-fn6){ref-type="fn"}           511                    87                 1 (ref)        416    91        1 (ref)
  * *\<37 weeks and PE/HIP                                             53                    73            0.82 (0.62, 1.09)    61    98   1.14 (0.86, 1.49)

Abbreviations: CI=confidence intervals; HIP=hypertension in pregnancy; HR=hazard ratio; PE=preeclampsia/eclampsia.

Cases/100 000 person-years, unadjusted.

Adjusted for age, birth cohort, parity, age at first birth and marital status at first birth.

*P*-value from LR-test of interaction term 0.23.

*P*-value from LR-test of interaction term 0.51.

*P*-value from LR-test of interaction term 0.18.

###### Duration of first pregnancy and breast cancer risk in 919 712 Norwegian women, stratified by PE/HIP status

                                           **Normotensive**   **PE/HIP**                                 
  --------------------------------------- ------------------ ------------ ------------------- ----- ---- -------------------
  *Duration of first pregnancy (weeks)*                                                                  
   \<32                                          200              87            1 (ref)        21    88        1 (ref)
   32--36                                        724              89       1.01 (0.86, 1.18)   93    84   0.83 (0.51, 1.33)
   37                                            565              88       0.99 (0.84, 1.17)   52    76   0.74 (0.45, 1.23)
   38                                            1211             85       0.96 (0.82, 1.11)   80    69   0.68 (0.42, 1.11)
   39                                            2660             85       0.94 (0.82, 1.09)   163   85   0.81 (0.51, 1.27)
   40                                            4036             86       0.95 (0.82, 1.09)   162   68   0.64 (0.40, 1.01)
   41                                            3326             83       0.92 (0.80, 1.06)   100   58   0.55 (0.34, 0.88)
   ⩾42                                           2391             81       0.90 (0.78, 1.04)   72    58   0.56 (0.34, 0.91)
                                                                                                                   
   Per week[c](#t6-fn4){ref-type="fn"}          15 113            84       0.99 (0.98, 1.00)   743   71   0.95 (0.93, 0.98)

Abbreviations: CI=confidence intervals; HIP=hypertension in pregnancy; HR=hazard ratio; PE=preeclampsia/eclampsia.

Cases/100 000 person-years, unadjusted.

Adjusted for age, birth cohort and parity, age at first birth and marital status at first birth.

*P*-value from LR-test of interaction term 0.22.

###### Selected characteristics and main results of previous studies of hypertensive diseases in pregnancy and breast cancer risk[a](#t7-fn2){ref-type="fn"}

  **Study and location**     **Cases/controls**   **Age at diagnosis (years)**   **Exposure assessment**                    **Exposure (prevalence**[b](#t7-fn3){ref-type="fn"}**, %)**       **HR/RR/OR (95% CI)**                               **Covariates**
  -------------------------- -------------------- ------------------------------ ------------------------------------------ ----------------------------------------------------------------- --------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Cohort studies*                                                                                                                                                                                                                                
   [@bib7], United States    146/3658             Mean 54.2                      Birth records                              P in any pregnancy (NR) Blood pressure increase Q1 *vs* Q4 (NR)   0.60[c](#t7-fn4){ref-type="fn"} 0.50 (0.31, 0.82)   Age Age, birth year, parity, age at first birth, maternal weight gain
                                                                                                                                                                                                                                                   
   [@bib17], Sweden          870/40 081           Range 25--71 Median 48         Swedish Birth Register (ICD-8, ICD-9)      P/HIP in any pregnancy (8.3)                                      No association (estimate NR)                        NR
                                                                                                                                                                                                                                                   
   [@bib6], Sweden           2216/311 803         95% of cases \<50              Swedish Birth Register (ICD-8, ICD-9)      PE/HIP in first pregnancy (6.8)                                   1.05[c](#t7-fn4){ref-type="fn"}                     ---
                                                                                                                                                                                                                                                   
   [@bib31], Norway          5474/689 183         Range \<30--80                 Medical Birth Registry of Norway (ICD-8)   PE/HIP in first pregnancy (6.2)                                   0.81 (0.71, 0.91)                                   Age, year of diagnosis, age at first birth, and parity
                                                                                                                                                                                                                                                   
   [@bib30], Norway          9160/691 846         Range \<30--84                 Medical Birth Registry of Norway (ICD-8)   PE/HIP in first pregnancy (6.2)                                   0.86 (0.78, 0.94)                                   Age, age at first birth, duration of pregnancy, parity, marital status, and offspring sex
                                                                                                                                                                                                                                                   
   [@bib5], Israel           2024/35 903          NR                             Birth records                              P in any pregnancy (2.9)                                          1.37 (1.06, 1.78)                                   Age at first birth and parity
                                                                                                                                                                                                                                                   
   [@bib15], United States   1768/29 691          Postmenopausal \<80            Self-reported                              P in last pregnancy (NR) P in other pregnancy (NR)                0.98 (0.73, 1.33) 0.77 (0.58, 1.02)                 Age, race, family history of breast cancer, age at menarche, hormone therapy use, body mass index, and parity
                                                                                                                                                                                                                                                   
  *Case--control studies*                                                                                                                                                                                                                         
   [@bib20], United States   314/628              All cases \<45                 Birth records                              PE in first pregnancy (2.4)                                       0.28 (0.08, 1.00)                                   Location and time of birth (matched), age at first birth
                                                                                                                                                                                                                                                   
   [@bib25], United States   4668/4635            Range 20--54                   Self-reported                              HT before or during last pregnancy (4.9)                          0.73 (0.59, 0.92)                                   Age and geographic region (matched), parity, age at first term pregnancy, and total duration of breast feeding. Body mass (not included in final model)
                                                                                                                                                                                                                                                   
   [@bib22], Italy           2569/2588            Range 23--74 Median 55         Self-reported                              HIP in any pregnancy (0.5)                                        1.8 (1.0, 3.4)                                      Study area, age, education, parity, body mass index, and menopausal status
                                                                                                                                                                                                                                                   
   [@bib28], United States   1236/1162            Range 20--44                   Self-reported                              PE in any pregnancy (10.4) HIP in any pregnancy (13.8)            0.81 (0.61, 1.1) 0.94 (0.73, 1.2)                   Age and site (matched), race, parity, age at first birth, body mass index, and menopausal status
                                                                                                                                                                                                                                                   
   [@bib12], United States   2404/9638            Range 22--55 Mean 37.6         Birth records                              P in first pregnancy (4.1)                                        0.86 (0.67, 1.12)                                   County and date of delivery (matched), age, and age at first birth
                                                                                                                                                                                                                                                   
   [@bib24], United States   1303/1374            Range 20--98                   Self-reported                              PE/HIP in any pregnancy (13.6)                                    0.71 (0.55, 0.93)                                   Age, age at first birth, body mass index, parity, smoking status, menopausal status, age at menarche, lactation, family history of breast cancer, ethnicity, and education

Abbreviations: CI=confidence interval; HIP=hypertension in pregnancy; HR=hazard ratio; HT=hypertension; ICD=International Classification of Diseases; NR=not reported; OR=odds ratio; P=preeclampsia; PE=preeclampsia/eclampsia; Q1=lowest quartile; Q4=highest quartile; RR=relative risk.

Only studies referred to in the discussion are included.

Among all participants in cohort studies and among controls only in case--control studies.

Only incidence rates reported.
